Universal 4SCAR7U Targeting CD7-positive Malignancies

Sponsor
Shenzhen Geno-Immune Medical Institute
Study ID
NCT05995028
Phase
PHASE1
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
6 Months - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Universal CD7-specific CAR gene-engineered T cells — BIOLOGICAL
    Infusion of 4SCAR7U T cells

Study Details

The purpose of this clinical trial is to assess the feasibility, safety and efficacy of universal CAR T cells based on 4SCAR7U design against CD7-positive hematological malignancies using CD7 specific universal CAR T cells. The study also aims to learn more about the function of CD7 targeting CAR T cells and their persistence in patients of hematological malignancies.

Key Dates

First listed
Aug 16, 2023
Start date
Jun 30, 2027
Status verified
Aug 2026
Primary completion
Jul 31, 2028
Completion
Dec 31, 2028

Study Design

Enrollment
30 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Universal 4SCAR7U cells to treat CD7-positive hematological malignancies

Primary Outcome Measure

Safety of infusion [ Time Frame: 6 months ]

Central Contacts

Find similar trials

Nationwide
Leukemia (other) trialsOncology trialsBlood cancer trials

Related Studies